Literature DB >> 30702194

Testing for hepatitis C virus infection in UK prisons: What actually happens?

Kathryn Jack1, Brian J Thomson1, William L Irving1.   

Abstract

Prisons are a key demographic in the drive to eradicate hepatitis C virus (HCV) as a major public health threat. We have assessed the impact of the recently introduced national opt-out policy on the current status of HCV testing in 14 prisons in the East Midlands (UK). We analysed testing rates pre- and post-introduction of opt-out testing, together with face-to-face interviews with prison healthcare and management staff in each prison. In the year pre-opt-out, 1972 people in prison (PIP) were tested, compared to 3440 in the year following opt-out. From July 2016 to June 2017, 2706 people were tested, representing 13.5% of all prison entrants (median 16.6%, range 7.6%-40.7%). Factors correlating with testing rates were as follows: pre-admission location of the PIP (another prison or the community, OR 2.2, 95% CI 1.9-2.3, P < 0.001); whether the PIP could access health care independently of prison officers (OR 1.7, 95% CI 1.5-1.8, P < 0.001); the absence of out-reach services for HCV treatment (OR 1.3, 95% CI 1.2-1.5, P < 0.001), whether >50% of PIP reported ease of access to a nurse (OR 2.0, 95% CI 1.8-2.2, P < 0.001), and whether prison health care was supplied by private or NHS providers (OR 1.3, 95% CI 1.2-1.5, P < 0.001). Testing rates remained far below the minimum national opt-out target of 50%. Inadequacy of healthcare facilities and constraints imposed by adherence to prison regimens were cited by healthcare and management staff at all prisons. Without radical change, the prison estate may be intrinsically incapable of supporting NHSE to deliver the HCV elimination strategy.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic viral hepatitis; diagnostic virology; hepatitis C; prisons

Mesh:

Year:  2019        PMID: 30702194     DOI: 10.1111/jvh.13071

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  2 in total

1.  Liver function tests in primary care provide a key opportunity to diagnose and engage patients with hepatitis C.

Authors:  A McLeod; S J Hutchinson; A Weir; S Barclay; J Schofield; C Gillespie Frew; D J Goldberg; M Heydtmann; E Wilson-Davies
Journal:  Epidemiol Infect       Date:  2022-06-27       Impact factor: 4.434

2.  The impact of direct-acting antivirals on hepatitis C viraemia among people who inject drugs in England; real-world data 2011-2018.

Authors:  Megan Bardsley; Ellen Heinsbroek; Ross Harris; Sara Croxford; Claire Edmundson; Vivian Hope; Nasra Hassan; Samreen Ijaz; Sema Mandal; Justin Shute; Sharon J Hutchinson; Matthew Hickman; Katy Sinka; Emily Phipps
Journal:  J Viral Hepat       Date:  2021-07-29       Impact factor: 3.517

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.